The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part
elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin …

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is
central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane …

Genomic studies have identified somatic alterations in the majority of myeloproliferative
neoplasms (MPN) patients, including JAK2 mutations in the majority of MPN patients and …

Frameshift mutations in the calreticulin (CALR) gene are seen in about 30% of essential
thrombocythemia and myelofibrosis patients. To address the contribution of the CALR …

Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic
stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis …

Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive
production of mature blood cells. In the majority of classic MPN—polycythemia vera …

We studied the relationship between JAK2 (V617F) mutant allele burden and clinical
phenotype, disease progression and survival in patients with polycythemia vera (PV). The …

Janus kinase 2 (valine to phenylalanine at residue 617)(JAK2 V617F) mutations lead to
myeloproliferative neoplasms associated with elevated myeloid, erythroid, and …

Aberrant activation of the JAK/STAT pathway has been reported in a variety of disease
states, including inflammatory conditions, hematologic malignancies, and solid tumors. For …

We report a Jak2V617F knockin mouse myeloproliferative neoplasm (MPN) model
resembling human polycythemia vera (PV). The MPN is serially transplantable and we …